A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Acadia ACP-101-303
What is the goal of the study?
This is a long-term, OLE study to evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS. Subjects who complete the antecedent double-blind study (ACP-101-302) will be invited to participate in the present study. The subject or legally acceptable representative (LAR) must provide written consent prior to the procedures being performed at the Week 12/end-of-treatment (EOT) visit of the antecedent study. A caregiver must also provide written consent to participate as an informant in study assessments prior to the procedures being performed at the Week 12/end-of-treatment (EOT) visit of the antecedent study. The data gathered at the Week 12/EOT visit of the antecedent study will serve as the baseline data of the present study.
Who can participate in the study?
Please contact the study team listed below to learn more.